Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Pharmaceuticals, Opko Health, Ophthalmic Technologies, Isis Pharmaceuticals, Excaliard Pharmaceuticals

Premium
Alnylam Issued German RNAi Patent
 
Alnylam Pharmaceuticals this week said that the German Patent Office has granted a patent from the company’s Kreutzer-Limmer I patent series, which claims siRNA drugs and their use as human therapeutics.
 
Specifically, the patent — DE 10080167 — covers siRNA 15 to 49 nucleotides in length, Alnylam said.
 
Alnylam noted that patents from the Kreutzer-Limmer I family have been licensed to four pharmaceutical partners, seven biotech firms, and 15 research reagent and services shops.
 

 
Opko Closes Acquisition of Ocular Imaging Firm
 
Opko Health said this week that it has completed its previously announced acquisition of Canadian ocular imaging systems provider Ophthalmic Technologies.
 
Specific terms of the deal were not disclosed.
 
"Our team believes there is the potential for powerful synergies between Opko’s therapeutics pipeline and the diagnostic systems and devices used by eye care professionals, and we expect [Ophthalmic Technologies] to continue to play an important strategic role in Opko’s plans for a broadly based ophthalmic business,” Rishard Weitz, president of Ophthalmic Technologies, said in a statement.
 
Opko is developing the phase III siRNA-based drug bevasiranib for wet age-related macular degeneration, among other RNAi and non-RNAi drugs (see RNAi News, 9/27/2007).
 

 
Isis, Excaliard Form Antisense Drug-Development Collaboration
 
Isis Pharmaceuticals and Excaliard Pharmaceuticals said this week that they will collaborate on the discovery and development of antisense drugs for fibrotic diseases, including scarring.
 
Under the deal, Isis has granted Excaliard an exclusive, worldwide license to develop certain of its antisense drugs for fibrotic indications. In exchange, Excaliard made an undisclosed upfront equity payment to Isis and paid $1 million in cash for the licensing of a particular gene target.
 
Isis also stands to receive milestones and royalties tied to the development and commercialization of antisense drugs developed by Excaliard.
 
Additional terms were not disclosed.